Skip to main content

RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires

Written by Customer Service on . Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Jennifer Nicholson as Senior Vice President of Regulatory Affairs and Quality Assurance and Adnan Rahman as Vice President of Commercial.

“It is a pleasure to welcome both Jennifer and Adnan to the RAPT leadership team at this exciting time of growth for the Company,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “The combination of their regulatory, commercial and marketing expertise is invaluable as we advance our RPT193 program into late stage trials in atopic dermatitis and asthma and continue development of FLX475 program in multiple cancer indications.”

Jennifer Nicholson
Jennifer brings over 20 years of biotechnology and pharmaceutical industry regulatory expertise, with significant experience across all stages of development in oncology including hematologic malignancies and solid tumors. Most recently, she served as Vice President of Regulatory Affairs at Kronos Bio. Prior to Kronos Bio, she was Head of Global Regulatory Science at Acerta Pharma, a member of the AstraZeneca Group.  Jennifer was the Global Regulatory Lead for the Calquence® (acalabrutinib) US NDA, which was granted accelerated approval in 2017, as well as for subsequent global filings. Prior to joining Acerta, Jennifer was Senior Director of Regulatory Affairs at Bavarian Nordic, where she focused on immuno-oncology and vaccine products. Earlier in her career, Jennifer worked as the Global Regulatory Lead on various hematology and oncology products at Jazz Pharmaceuticals, Onyx Pharmaceuticals and Genentech. Jennifer holds a B.S. in Biochemistry and Cell Biology from the University of California, San Diego and an M.H.A. from the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill.

Adnan Rahman
Adnan brings over 20 years of biopharmaceutical commercial and marketing expertise. Most recently, he served as Global Commercial Lead of Dermatology at Arena Pharmaceuticals, acquired by Pfizer., where he led global commercial strategy for its principal asset, Etrasimod, in atopic dermatitis and alopecia areata. Prior to Arena Pharmaceuticals, he was U.S. Commercial Director of XGEVA® (denosumab) at Amgen and held various senior marketing positions in oncology, bone health and inflammation business units. Earlier in his career, Adnan held various marketing positions at Pharmacia and Procter & Gamble. Adnan holds an M.B.A. from Rutgers University and an M.A and B.A. in Electrical Engineering from University of Cambridge.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com

RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.